Management of Idiopathic Pulmonary Fibrosis

Clinics in Chest Medicine

Volumn 33, Issue 1, 2012, Pages 85-94

  Cerri, Stefania ^a   Spagnolo, Paolo ^a   Luppi, Fabrizio ^a   Richeldi, Luca ^a  

^a UNIVERSITY OF MODENA AND REGGIO EMILIA   (Italy)

Author keywords

Comorbidities; Corticosteroids; Idiopathic pulmonary fibrosis; Pirfenidone; Randomized controlled trials

Indexed keywords

ACETYLCYSTEINE; AMBRISENTAN; ANTIFIBROTIC AGENT; ANTIINFLAMMATORY AGENT; AZATHIOPRINE; BCR ABL PROTEIN; BOSENTAN; COLCHICINE; CORTICOSTEROID; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; ENDOTHELIN RECEPTOR ANTAGONIST; ETANERCEPT; GAMMA1B INTERFERON; HISTAMINE H2 RECEPTOR ANTAGONIST; IMATINIB; IMMUNOMODULATING AGENT; METHYLPREDNISOLONE; OXYGEN; PIRFENIDONE; PLACEBO; PLATELET DERIVED GROWTH FACTOR RECEPTOR; POLYMYXIN B; PREDNISONE; PROTON PUMP INHIBITOR; SILDENAFIL; TACROLIMUS;

CLINICAL PRACTICE; COMORBIDITY; DECISION MAKING; DISEASE COURSE; DISEASE EXACERBATION; DRUG EFFICACY; DRUG SAFETY; EVIDENCE BASED PRACTICE; FIBROSING ALVEOLITIS; GASTROESOPHAGEAL REFLUX; HIGH RESOLUTION COMPUTER TOMOGRAPHY; HUMAN; LIFESTYLE MODIFICATION; LUNG FUNCTION; LUNG TRANSPLANTATION; MORBIDITY; OXYGEN THERAPY; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROGNOSIS; PROGRESSION FREE SURVIVAL; PULSE OXIMETRY; QUALITY OF LIFE; REVIEW; RISK REDUCTION; STOMACH FUNDOPLICATION; SURVIVAL; VITAL CAPACITY;

ACUTE DISEASE; ANTI-INFLAMMATORY AGENTS; CELL PROLIFERATION; CHRONIC DISEASE; COMORBIDITY; FIBRINOLYTIC AGENTS; GASTROESOPHAGEAL REFLUX; HUMANS; IDIOPATHIC PULMONARY FIBROSIS; IMMUNOLOGIC FACTORS; LUNG TRANSPLANTATION; MYOFIBROBLASTS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TREATMENT OUTCOME;

EID: 84857390959     PISSN: 02725231     EISSN: 15578216     Source Type: Journal    
DOI: 10.1016/j.ccm.2011.11.005     Document Type: Review

References (67)

1. Raghu G., Collard H.R., Egan J.J., et al. Idiopathic pulmonary fibrosis: evidence based guidelines for diagnosis and management. Am J Respir Crit Care Med 2011, 183(6):788-824.
2. Schunemann H.J., Jaeschke R., Cook D.J., et al. An official ATS statement: grading the quality of evidence and strength of recommendations in ATS guidelines and recommendations. Am J Respir Crit Care Med 2006, 174(5):605-614.
3. Richeldi L., Davies H.R., Ferrara G., et al. Corticosteroids for idiopathic pulmonary fibrosis. Cochrane Database Syst Rev 2003, 3. CD002880. Edited; published in Issue 2, 2010.
4. Richeldi L., Davies H.R., Spagnolo P., et al. Corticosteroids for idiopathic pulmonary fibrosis. Cochrane Database Syst Rev 2010, 2. CD002880.
5. Spagnolo P., Del Giovane C., Luppi F., et al. Non-steroid agents for idiopathic pulmonary fibrosis. Cochrane Database Syst Rev 2010, 9. CD003134.
6. Demedts M., Behr J., Buhl R., et al. High-dose acetylcysteine in idiopathic pulmonary fibrosis. N Engl J Med 2005, 353(21):2229-2242.
7. King T.E., Pardo A., Selman M. Idiopathic pulmonary fibrosis. Lancet 2011, 378(9807):1949-1961.
8. Gauldie J., Kolb M. Animal models of pulmonary fibrosis: how far from effective reality?. Am J Physiol Lung Cell Mol Physiol 2008, 294(2):L151.
9. Noble P.W., Richeldi L., Kaminski N. End of an ERA: lessons from negative clinical trials in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2011, 184(1):4-5.
10. Ziesche R., Hofbauer E., Wittmann K., et al. A preliminary study of long-term treatment with interferon gamma-1b and low-dose prednisolone in patients with idiopathic pulmonary fibrosis. N Engl J Med 1999, 341(17):1264-1269.
11. Raghu G., Brown K.K., Bradford W.Z., et al. A placebo-controlled trial of interferon gamma-1b in patients with idiopathic pulmonary fibrosis. N Engl J Med 2004, 350(2):125-133.
12. King T.E., Albera C., Bradford W.Z., et al. Effect of interferon gamma-1b on survival in patients with idiopathic pulmonary fibrosis (INSPIRE): a multicentre, randomised, placebo-controlled trial. Lancet 2009, 374(9685):222-228.
13. Luppi F., Losi M., D'Amico R., et al. Endogenous blood maximal interferon-gamma production may predict response to interferon-gamma 1beta treatment in patients with idiopathic pulmonary fibrosis. Sarcoidosis Vasc Diffuse Lung Dis 2009, 26(1):64-68.
14. Casoni G.L., Chilosi M., Romagnoli M., et al. Another "chance" for interferon gamma 1b?. Sarcoidosis Vasc Diffuse Lung Dis 2011, 28(1):79-80.
15. King T.E., Behr J., Brown K.K., et al. BUILD-1: a randomized placebo-controlled trial of bosentan in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2008, 177(1):75-81.
16. King T.E., Brown K.K., Raghu G., et al. BUILD-3: a randomized, controlled trial of bosentan in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2011, 184(1):92-99.
17. Raghu G., Brown K.K., Costabel U., et al. Treatment of idiopathic pulmonary fibrosis with etanercept: an exploratory, placebo-controlled trial. Am J Respir Crit Care Med 2008, 178(9):948-955.
18. Daniels C.E., Lasky J.A., Limper A.H., et al. Imatinib treatment for idiopathic pulmonary fibrosis: Randomized placebo-controlled trial results. Am J Respir Crit Care Med 2010, 181(6):604-610.
19. Richeldi L., Brown K.K., Costabel U., et al. The oral triple kinase inhibitor BIBF 1120 reduces decline in lung function in patients with idiopathic pulmonary fibrosis (IPF): results from the tomorrow study. Am J Respir Crit Care Med 2011, 183:A5303.
20. Richeldi L., Costabel U., Selman M., et al. Efficacy of a tyrosine kinase inhibitor in idiopathic pulmonary fibrosis. N Engl J Med 2011, 365(12):1079-1087.
21. Kubo H., Nakayama K., Yanai M., et al. Anticoagulant therapy for idiopathic pulmonary fibrosis. Chest 2005, 128(3):1475-1482.
22. Raghu G., Johnson W.C., Lockhart D., et al. Treatment of idiopathic pulmonary fibrosis with a new antifibrotic agent, pirfenidone: Results of a prospective, open-label phase II study. Am J Respir Crit Care Med 1999, 159(4 I):1061-1069.
23. Azuma A., Nukiwa T., Tsuboi E., et al. Double-blind, placebo-controlled trial of pirfenidone in patients with idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2005, 171(9):1040-1047.
24. Taniguchi H., Ebina M., Kondoh Y., et al. Pirfenidone in idiopathic pulmonary fibrosis. Eur Respir J 2010, 35(4):821-829.
25. Noble P.W., Albera C., Bradford W.Z., et al. Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trials. Lancet 2011, 377(9779):1760-1769.
26. King T.E., Safrin S., Starko K.M., et al. Analyses of efficacy end points in a controlled trial of interferon-gamma1b for idiopathic pulmonary fibrosis. Chest 2005, 127(1):171-177.
27. Collard H.R., King T.E., Bartelson B.B., et al. Changes in clinical and physiologic variables predict survival in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2003, 168(5):538-542.
28. du Bois R.M., Weycker D., Albera C., et al. Ascertainment of individual risk of mortality for patients with idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2011, 184(4):459-466.
29. Nathan S.D., Shlobin O.A., Ahmad S., et al. Serial development of pulmonary hypertension in patients with idiopathic pulmonary fibrosis. Respiration 2008, 76(3):288-294.
30. Glaser S., Noga O., Koch B., et al. Impact of pulmonary hypertension on gas exchange and exercise capacity in patients with pulmonary fibrosis. Respir Med 2009, 103(2):317-324.
31. Collard H.R., Anstrom K.J., Schwarz M.I., et al. Sildenafil improves walk distance in idiopathic pulmonary fibrosis. Chest 2007, 131(3):897-899.
32. Zisman D.A., Schwarz M., Anstrom K.J., et al. A controlled trial of sildenafil in advanced idiopathic pulmonary fibrosis. N Engl J Med 2010, 363(7):620-628.
33. Raghu G., King T.E., Behr J., et al. Quality of life and dyspnoea in patients treated with bosentan for idiopathic pulmonary fibrosis (BUILD-1). Eur Respir J 2010, 35(1):118-123.
34. Raghu G., Weycker D., Edelsberg J., et al. Incidence and prevalence of idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2006, 174(7):810-816.
35. Lee J.S., Collard H.R., Raghu G., et al. Does chronic microaspiration cause idiopathic pulmonary fibrosis?. Am J Med 2010, 123(4):304-311.
36. Tobin R.W., Pope C.E., Pellegrini C.A., et al. Increased prevalence of gastroesophageal reflux in patients with idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 1998, 158(6):1804-1808.
37. Raghu G., Yang S.T., Spada C., et al. Sole treatment of acid gastroesophageal reflux in idiopathic pulmonary fibrosis: a case series. Chest 2006, 129(3):794-800.
38. Linden P.A., Gilbert R.J., Yeap B.Y., et al. Laparoscopic fundoplication in patients with end-stage lung disease awaiting transplantation. J Thorac Cardiovasc Surg 2006, 131(2):438-446.
39. Lee J.S., Ryu J.H., Elicker B.M., et al. Gastroesophageal reflux therapy is associated with longer survival in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2011 Jun 23, [Epub ahead of print].
40. Savarino E., Bazzica M., Zentilin P., et al. Gastroesophageal reflux and pulmonary fibrosis in scleroderma: a study using pH-impedance monitoring. Am J Respir Crit Care Med 2009, 179(5):408-413.
41. Gulmez S.E., Holm A., Frederiksen H., et al. Use of proton pump inhibitors and the risk of community-acquired pneumonia: a population-based case-control study. Arch Intern Med 2007, 167(9):950-955.
42. Yang Y.X., Lewis J.D., Epstein S., et al. Long-term proton pump inhibitor therapy and risk of hip fracture. JAMA 2006, 296(24):2947-2953.
43. Collard H.R., Moore B.B., Flaherty K.R., et al. Acute exacerbations of idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2007, 176(7):636-643.
44. Hyzy R., Huang S., Myers J., et al. Acute exacerbation of idiopathic pulmonary fibrosis. Chest 2007, 132(5):1652-1658.
45. Agarwal R., Jindal S.K. Acute exacerbation of idiopathic pulmonary fibrosis: a systematic review. Eur J Intern Med 2008, 19(4):227-235.
46. Inase N., Sawada M., Ohtani Y., et al. Cyclosporin A followed by the treatment of acute exacerbation of idiopathic pulmonary fibrosis with corticosteroid. Intern Med 2003, 42(7):565-570.
47. Sakamoto S., Homma S., Miyamoto A., et al. Cyclosporin A in the treatment of acute exacerbation of idiopathic pulmonary fibrosis. Intern Med 2010, 49(2):109-115.
48. Horita N., Akahane M., Okada Y., et al. Tacrolimus and steroid treatment for acute exacerbation of idiopathic pulmonary fibrosis. Intern Med 2011, 50(3):189-195.
49. Enomoto N., Suda T., Uto T., et al. Possible therapeutic effect of direct haemoperfusion with a polymyxin B immobilized fibre column (PMX-DHP) on pulmonary oxygenation in acute exacerbations of interstitial pneumonia. Respirology 2008, 13(3):452-460.
50. Seo Y., Abe S., Kurahara M., et al. Beneficial effect of polymyxin B-immobilized fiber column (PMX) hemoperfusion treatment on acute exacerbation of idiopathic pulmonary fibrosis. Intern Med 2006, 45(18):1033-1038.
51. Yoshida T., Kodama M., Tamura Y., et al. Nihon Kokyuki Gakkai Zasshi 2007, 45(11):890-897. [in Japanese].
52. De Vries J., Kessels B.L., Drent M. Quality of life of idiopathic pulmonary fibrosis patients. Eur Respir J 2001, 17(5):954-961.
53. Ries A.L., Bauldoff G.S., Carlin B.W., et al. Pulmonary rehabilitation: joint ACCP/AACVPR evidence-based clinical practice guidelines. Chest 2007, 131(Suppl 5):4S-42S.
54. Douglas W.W., Ryu J.H., Schroeder D.R. Idiopathic pulmonary fibrosis: Impact of oxygen and colchicine, prednisone, or no therapy on survival. Am J Respir Crit Care Med 2000, 161(4 Pt 1):1172-1178.
55. Nici L., Donner C., Wouters E., et al. American Thoracic Society/European Respiratory Society statement on pulmonary rehabilitation. Am J Respir Crit Care Med 2006, 173(12):1390-1413.
56. Spruit M.A., Janssen D.J., Franssen F.M., et al. Rehabilitation and palliative care in lung fibrosis. Respirology 2009, 14(6):781-787.
57. Holland A.E., Hill C.J., Conron M., et al. Short term improvement in exercise capacity and symptoms following exercise training in interstitial lung disease. Thorax 2008, 63(6):549-554.
58. Stern J.B., Mal H., Groussard O., et al. Prognosis of patients with advanced idiopathic pulmonary fibrosis requiring mechanical ventilation for acute respiratory failure. Chest 2001, 120(1):213-219.
59. Mallick S. Outcome of patients with idiopathic pulmonary fibrosis (IPF) ventilated in intensive care unit. Respir Med 2008, 102(10):1355-1359.
60. Saydain G., Islam A., Afessa B., et al. Outcome of patients with idiopathic pulmonary fibrosis admitted to the intensive care unit. Am J Respir Crit Care Med 2002, 166(6):839-842.
61. Beckmann A., Benk C., Beyersdorf F., et al. Position article for the use of extracorporeal life support in adult patients. Eur J Cardiothorac Surg 2011, 40(3):676-680.
62. Allen S., Raut S., Woollard J., et al. Low dose diamorphine reduces breathlessness without causing a fall in oxygen saturation in elderly patients with end-stage idiopathic pulmonary fibrosis. Palliat Med 2005, 19(2):128-130.
63. Ryerson C.J., Berkeley J., Carrieri-Kohlman V.L., et al. Depression and functional status are strongly associated with dyspnea in interstitial lung disease. Chest 2011, 139(3):609-616.
64. Trulock E.P., Edwards L.B., Taylor D.O., et al. The Registry of the International Society for Heart and Lung Transplantation: twentieth official adult lung and heart-lung transplant report-2003. J Heart Lung Transplant 2003, 22(6):625-635.
65. Yusen R.D., Shearon T.H., Qian Y., et al. Lung transplantation in the United States, 1999-2008. Am J Transplant 2010, 10(4 Pt 2):1047-1068.
66. Mason D.P., Brizzio M.E., Alster J.M., et al. Lung transplantation for idiopathic pulmonary fibrosis. Ann Thorac Surg 2007, 84(4):1121-1128.
67. Keating D., Levvey B., Kotsimbos T., et al. Lung transplantation in pulmonary fibrosis: challenging early outcomes counterbalanced by surprisingly good outcomes beyond 15 years. Transplant Proc 2009, 41(1):289-291.